| Name | Vazegepant hydrochloride |
|---|
| Description | Vazegepant (BHV-3500) hydrochloride is a highly affinity CGRP receptor antagonist (hCGRP Ki= 0.023 nM). Vazegepant hydrochloride is the first intranasal gepant for migraine. Vazegepant hydrochloride may be helpful in effective management of COVID-19 associated pulmonary inflammation[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
Ki: 0.023 nM (hCGRP)[3] |
| References |
| Molecular Formula | C36H47ClN8O3 |
|---|---|
| Molecular Weight | 675.26 |